Sodium-Glucose Cotransporter 2 억제제 사용 후 발생한 케톤산증 1예 |
전제혁, 최경진, 우영민, 박예림, 박윤규, 김원준, 심명숙, 김진엽 |
|
A Case of Diabetic Ketoacidosis Induced by Sodium-Glucose Cotransporter 2 Inhibitor. |
Jae Hyuck Jun, Kyung Jin Choe, Yeong Min Woo, Ye Rim Park, Yoon Kyoo Park, Won Jun Kim, Myoung Sook Shim, Jin Yeob Kim |
Department of Internal Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Korea. kozmozman@gnah.co.kr |
|
Abstract |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral antihyperglycemic drugs; inhibition of the cotransporter allows for increased renal glucose excretion that consequently leads to reduced plasma glucose level. We report a rare case of a 73-year-old woman with type 2 diabetes mellitus who developed severe ketoacidosis caused by an SGLT2 inhibitor. At admission, severe ketoacidosis with arterial PH 6.99 was observed, though her serum glucose level of 232 mg/dL was not excessively high. It is necessary to pay attention to patients with type 2 diabetes being treated with an SGLT2 inhibitor, as anorexia, diarrhea, dehydration, and weight loss can develop in conjunction with a high fat/protein diet. |
Key Words:
Diabetes mellitus, Ketosis, Sodium-glucose cotransporter 2 |
|